- Home
- ABUS vs ESQ Comparison
ABUS vs ESQ Comparison
Compare ABUS & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- ESQ
- Stock Information
- Founded
- ABUS 2005
- ESQ 2006
- Country
- ABUS United States
- ESQ United States
- Employees
- ABUS N/A
- ESQ N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- ESQ Commercial Banks
- Sector
- ABUS Health Care
- ESQ Finance
- Exchange
- ABUS Nasdaq
- ESQ Nasdaq
- Market Cap
- ABUS 711.2M
- ESQ 838.1M
- IPO Year
- ABUS N/A
- ESQ 2017
- Fundamental
- Price
- ABUS $4.38
- ESQ $100.89
- Analyst Decision
- ABUS Strong Buy
- ESQ Hold
- Analyst Count
- ABUS 2
- ESQ 3
- Target Price
- ABUS $5.00
- ESQ $103.00
- AVG Volume (30 Days)
- ABUS 1.4M
- ESQ 67.5K
- Earning Date
- ABUS 11-05-2025
- ESQ 10-23-2025
- Dividend Yield
- ABUS N/A
- ESQ 0.69%
- EPS Growth
- ABUS N/A
- ESQ 12.45
- EPS
- ABUS N/A
- ESQ 5.39
- Revenue
- ABUS $15,416,000.00
- ESQ $126,841,000.00
- Revenue This Year
- ABUS $138.02
- ESQ N/A
- Revenue Next Year
- ABUS N/A
- ESQ $10.14
- P/E Ratio
- ABUS N/A
- ESQ $18.73
- Revenue Growth
- ABUS 53.23
- ESQ 12.91
- 52 Week Low
- ABUS $2.71
- ESQ $60.64
- 52 Week High
- ABUS $5.10
- ESQ $107.25
- Technical
- Relative Strength Index (RSI)
- ABUS 54.52
- ESQ 51.36
- Support Level
- ABUS $4.25
- ESQ $98.89
- Resistance Level
- ABUS $4.66
- ESQ $104.74
- Average True Range (ATR)
- ABUS 0.17
- ESQ 2.50
- MACD
- ABUS -0.03
- ESQ -0.33
- Stochastic Oscillator
- ABUS 41.67
- ESQ 23.92
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.